Kodiak Sciences Inc
Performance History
| Key Stats | |
|---|---|
| Open | $2.65 |
| Prev. Close | $2.66 |
| EPS | -5.19 |
| Dividend | $0.00 |
| Next Earnings Date | Aug 14, 2023 |
| Dividend Yield % | - |
| Market Cap | $130.65M |
| PE Ratio | - |
| low | high | |
|---|---|---|
| Day Range | 2.46 | 2.75 |
| 52 Week Range | 1.37 | 9.80 |
| Ratios | |
|---|---|
| P/B Ratio | 0.46 |
| Revenue | - |
| Operating M. % | 0.00% |
| Earnings | -$271.42M |
| Earnings Growth % | - |
| EBITDA Margin % | - |
| ROE % | -69.42% |
| EPS | -5.19 |
Score Breakdown
All Score (53 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
| KOD | Market | |
|---|---|---|
| Value | 67 | 42 |
| Quality | 38 | 46 |
| Ownership | 31 | 39 |
| Growth | 52 | 44 |
| Dividends | - | 32 |
All Score (53 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
Financial Forecast
AI Price Prediction
Analyst Ratings
Correlated Companies
About Kodiak Sciences Inc (KOD)
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
- ISN
- -
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Victor Perlroth M.D.
- Headquarters
- Palo Alto
- Employees
- 118
Keep an eye on Kodiak Sciences Inc
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
News
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.